JAK Inhibitors in Alopecia Areata: Clinical Rationale and FDA-Approved Therapies

Welcome back to another AJMC Insights series. In this episode titled, 'JAK Inhibitors in Alopecia Areata: Clinical Rationale and FDA-Approved Therapies', Arash Mostaghimi led the conversation about the following questions:

What was the clinical rationale for investigating JAK inhibitors in patients with alopecia areata (AA)?

What are the 3 FDA-approved options and how do their mechanisms of action differ from each other?

How do their dosing schedules differ from each other?

What are the strengths and limitations of each dosing schedule?

Arash Mostaghimi highlighted the scientific journey that led to Janus kinase (JAK) inhibitors becoming a treatment avenue for alopecia areata, beginning with a case report by Brett King in which a patient with psoriatic arthritis receiving tofacitinib experienced complete scalp hair regrowth despite also having AA. This observation was supported by a genome-wide association study that identified polymorphisms in the JAK-STAT pathway as more prevalent in patients with AA. Dr. Mostaghimi then outlined the three FDA-approved JAK inhibitors for AA — baricitinib, a once-daily JAK1/2 inhibitor available in 2 mg and 4 mg doses; ritlecitinib, a once-daily JAK3/TEK inhibitor dosed at 50 mg; and deuruxolitinib, a twice-daily JAK1/2 inhibitor dosed at 8 mg — and discussed the clinical significance of twice-daily dosing for deuruxolitinib based on its pharmacokinetic profile.

Throughout the conversation, the expert provided a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the next episode, 'Comparing the Clinical Trials of Baricitinib and Ritlecitinib in Alopecia Areata,' the panelist continues their discussion on alopecia areata and highlight the key efficacy and safety findings from the clinical trials that led to the approval of baricitinib and ritlecitinib, including how the trial designs and patient populations differed between the two agents.